DK1618098T3 - 1,2,4-oxadiazolbenzoesyreforbindelser og deres anvendelse til nonsens-bekæmpelse og behandling af en sygdom - Google Patents

1,2,4-oxadiazolbenzoesyreforbindelser og deres anvendelse til nonsens-bekæmpelse og behandling af en sygdom Download PDF

Info

Publication number
DK1618098T3
DK1618098T3 DK04759404.9T DK04759404T DK1618098T3 DK 1618098 T3 DK1618098 T3 DK 1618098T3 DK 04759404 T DK04759404 T DK 04759404T DK 1618098 T3 DK1618098 T3 DK 1618098T3
Authority
DK
Denmark
Prior art keywords
phenyl
oxadiazol
benzoic acid
fluoro
disease
Prior art date
Application number
DK04759404.9T
Other languages
English (en)
Inventor
Gary Mitchell Karp
Seongwoo Hwang
Guangming Chen
Neil Gregory Almstead
Young-Choon Moon
Original Assignee
Ptc Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ptc Therapeutics Inc filed Critical Ptc Therapeutics Inc
Application granted granted Critical
Publication of DK1618098T3 publication Critical patent/DK1618098T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/12—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/14—Thiadiazoles; Hydrogenated thiadiazoles condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Claims (30)

1
1. Forbindelse med formel (I):
hvor: Z er substitueret aryl med undtagelse af 4-cyanophenyl, substitueret eller usubstitueret heteroaryl udvalgt fra triazolyl, tetrazolyl, oxadiazolyl, furyl, benzofuranyl, thiophenyl, benzothiophenyl, benzoisoxazolyl, benzoisothi-azolyl, quinolinyl, pyrrolyl, indolyl, oxazolyl, benzoxazolyl, benzimidazolyl, benzothiazolyl, isoxazolyl, pyrazolyl, isothiazolyl, pyridazinyl, pyrazinyl, triazi-nyl, cinnolinyl, phthalazinyl, quinazolinyl, benzoquinazolinyl eller acridinyl, substitueret eller usubstitueret cycloalkyl, substitueret eller usubstitueret alkenyl, substitueret eller usubstitueret heterocyklus udvalgt fra morpholinyl, pyrrolidinonyl, pyrrolidinyl, hydantoinyl, valerolactamyl, oxiranyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothiophenyl eller tetrahy-drothiopyranyl, substitueret eller usubstitueret arylalkyl; eller Z er p-tolyl; (4-chlormethyl-phenyl); (4-ethyl-phenyl); o-tolyl; (3-methyl-thiophen-2-yl); (4-tert-butyl-phenyl); m-tolyl; (2,5-dimethyl-furan-3-yl); (4-pyrrol-1-yl-phenyl); (4-nitrophenyl); (4-isobutyl-phenyl); [3-(2-chlor-6-fluor-phenyl)-5-methyl-isoxazol-4-yl]; eller [3-(2-chlor-phenyl)-5-methyl-isoxazol-4-yl]; R1 er hydrogen, substitueret eller usubstitueret alkyl, substitueret eller usubstitueret cycloalkyl, substitueret eller usubstitueret heterocycloalkyl, substitueret eller usubstitueret aryl, substitueret eller usubstitueret heteroaryl eller -(CH2CH20)nR6; R2, R3, R4 og R5 uafhængigt er hydrogen, alkoxy eller halogen; R6 er hydrogen eller alkyl; n er et helt tal fra 1 til 7; og 2 termen "substitueret" betyder en gruppe, som er substitueret med en til fire substituenter, udvalgt fra halogen, trifluormethyl, trifluormethoxy, hydroxy, alkoxy, cycloalkyloxy, heterocyclooxy, oxo, alkanoyl, alkylcarbonyl, cycloal-kyl, aryl, aryloxy, aralkyl, alkanoyloxy, cyano, azido, amino, alkylamino, arylamino, aralkylamino, cycloalkylamino, heterocycloamino eller mono og disubstitueret amino, hvori den ene eller to substituenter på aminogruppen er udvalgt fra alkyl; hvor sådanne yderligere substituenter, når selve substituen-terne er yderligere substitueret, er udvalgt fra gruppen bestående af halogen, al kyl, alkoxy, aryl og aralkyl; eller et farmaceutisk acceptabelt salt, solvat eller hydrat deraf.
2. Forbindelse
ifølge krav 1 med formel II: (ii) hvor: Z er substitueret aryl med undtagelse af 4-cyanophenyl, substitueret eller usubstitueret heteroaryl udvalgt fra triazolyl, tetrazolyl, oxadiazolyl, furyl, benzofuranyl, thiophenyl, benzothiophenyl, benzoisoxazolyl, benzoisothi-azolyl, quinolinyl, pyrrolyl, indolyl, oxazolyl, benzoxazolyl, benzimidazolyl, benzothiazolyl, isoxazolyl, pyrazolyl, isothiazolyl, pyridazinyl, pyrazinyl, triazi-nyl, cinnolinyl, phthalazinyl, quinazolinyl, benzoquinazolinyl eller acridinyl, substitueret eller usubstitueret cycloalkyl, substitueret eller usubstitueret alkenyl, substitueret eller usubstitueret heterocyklus udvalgt fra morpholinyl, pyrrolidinonyl, pyrrolidinyl, hydantoinyl, valerolactamyl, oxiranyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothiophenyl eller tetrahy-drothiopyranyl, substitueret eller usubstitueret arylalkyl; eller Z er p-tolyl; (4-chlormethyl-phenyl); (4-ethyl-phenyl); o-tolyl; (3-methyl-thiophen-2-yl); (4-tert-butyl-phenyl); m-tolyl; (2,5-dimethyl-furan-3-yl); (4-pyrrol-1 -yl-phenyl); (4-nitrophenyl); (4-isobutyl-phenyl); [3-(2-chlor-6-fluor-phenyl)-5-methyl-isoxazol-4-yl]; eller [3-(2-chlor-phenyl)-5-methyl-isoxazol-4-yl]; og 3 R er hydrogen eller halogen; eller et farmaceutisk acceptabelt salt, solvat eller hydrat deraf.
3. Forbindelse ifølge krav 1 eller 2, hvor Z er p-tolyl; (4-chlormethyl-phenyl); (2-fluor-phenyl); (3,4-difluor-phenyl); (4-methoxy-phenyl); benzo[1,3]dioxol-5-yl; (4-ethyl-phenyl); o-tolyl; (2-chlor-phenyl); (3-methyl-thiophen-2-yl); ben-zo[b]thiophen-2-yl; (3-fluor-phenyl); (4-tert-butyl-phenyl); (2-methoxy-phenyl); (2,5-difluor-phenyl); thiophen-2-yl; (2,4-difluor-phenyl); (3-chlor-phenyl); m-tolyl; (4-trifluormethyl-phenyl); (4-fluor-phenyl); (3-methoxy-phenyl); (2,6-difluor-phenyl); (2,5-dimethyl-furan-3-yl); (4-pyrrol-1 -yl-phenyl); (3-dimethylamino-phenyl); biphenyl-4-yl; (4-dimethylamino-phenyl); ben-zo[c][1,2,5]oxadiazol-5-yl; (2-trifluormethyl-phenyl); furan-2-yl; (4-nitrophenyl); (3,4-dimethoxy-phenyl); (3-trifluormethoxy-phenyl); cyclohexyl; cyclopentyl; cyclopropyl; (4-pentyloxy-phenyl); (3,4,5-trimethoxy-phenyl); (4-isobutyl-phenyl); cyclobutyl; (1 -acetyl-piperidin-4-yl); isoxazol-5-yl; [3-(2-chlor-6-fluor-phenyl)-5-methyl-isoxazol-4-yl]; eller [3-(2-chlor-phenyl)-5-methyl-isoxazol-4- yi]-
4. Forbindelse ifølge krav 3, hvor Z er (2-fluor-phenyl); (3,4-difluor-phenyl); (2-chlor-phenyl); (3-fluor-phenyl); (2,5-difluor-phenyl); (2,4-difluor-phenyl); (3-chlor-phenyl); (4-fluor-phenyl); eller (2,6-difluor-phenyl).
5. Forbindelse ifølge krav 1 udvalgt fra gruppen bestående af: 3-((5-p-tolyl-[1,2,4]oxadiazol-3-yl)-benzoesyre; 3-[5-(4-chlormethyl-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoesyre; 3-[5-(2-fluor-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoesyre; 3-[5-(3,4-difluor-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoesyre; 3-[5-(4-methoxy-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoesyre; 3-((5-benzo[1,3]dioxol-5-yl-[1,2,4]oxadiazol-3-yl)-benzoesyre; 3-[5-(4-ethyl-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoesyre; 3-((5-o-tolyl-[1,2,4]oxadiazol-3-yl)-benzoesyre; 3-[5-(2-chlor-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoesyre; 3-[5-(3-methyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-benzoesyre; 3-((5-benzo[b]thiophen-2-yl-[1,2,4]oxadiazol-3-yl)-benzoesyre; 3-[5-(3-fluor-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoesyre; 3-[5-(4-tert-butyl-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoesyre; 3-[5-(2-methoxy-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoesyre; 4 3-[5-(2,5-difluor-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoesyre; 3-((5-thiophen-2-yl-[1,2,4]oxadiazol-3-yl)-benzoesyre; 3-((5-thiophen-2-ylmethyl-[1,2,4]oxadiazol-3-yl)-benzoesyre; 3-[5-(2,4-difluor-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoesyre; 3-[5-(3-chlor-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoesyre; 3-((5-m-tolyl-[1,2,4]oxadiazol-3-yl)-benzoesyre; 3-[5-(4-trifluormethyl-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoesyre; 3-[5-(4-fluor-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoesyre; 3-[5-(3-methoxy-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoesyre; 3-[5-(2,6-difluor-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoesyre; 3-[5-(2,5-dimethyl-furan-3-yl)-[1,2,4]oxadiazol-3-yl]-benzoesyre; 3-[5-(4-pyrrol-1-yl-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoesyre; 3-[5-(3-dimethylamino-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoesyre; 3-((5-biphenyl-4-yl-[1,2,4]oxadiazol-3-yl)-benzoesyre; 3-[5-(4-dimethylamino-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoesyre; 3-((5-benzo[c][1,2,5]oxadiazol-5-yl-[1,2,4]oxadiazol-3-yl)-benzoesyre; 3-[5-(2-trifluormethyl-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoesyre; 3-((5-furan-2-yl-[1,2,4]oxadiazol-3-yl)-benzoesyre; 3-[5-(4-nitrogen-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoesyre; 3-[5-(3,4-dimethoxy-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoesyre; 3-[5-(3-trifluormethoxy-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoesyre; 3-((5-cyclohexyl-[1,2,4]oxadiazol-3-yl)-benzoesyre; 3-((5-cyclopentyl-[1,2,4]oxadiazol-3-yl)-benzoesyre; 3-((5-cyclopropyl-[1,2,4]oxadiazol-3-yl)-benzoesyre; 3-[5-(4-pentyloxy-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoesyre; 3-[5-(3,4,5-trimethoxy-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoesyre; 3-[5-(4-isobutyl-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoesyre; 3-((5-cyclobutyl-[1,2,4]oxadiazol-3-yl)-benzoesyre; 3-[5-( 1 -acetyl-pi peridi n-4-yl)-[1,2,4]oxadiazol-3-yl]-benzoesyre; 3-((5-isoxazol-5-yl-[1,2,4]oxadiazol-3-yl)-benzoesyre; 3-{5-[3-(2-chlor-6-fluor-phenyl)-5-methyl-isoxazol-4-yl]-[1,2,4]oxadiazol-3-yl}-benzoesyre; 3-((5-isopropyl-[1,2,4]oxadiazol-3-yl)-benzoesyre; 3-((5-tert-butyl-[1,2,4]oxadiazol-3-yl)-benzoesyre; 3-((5-butyl-[1,2,4]oxadiazol-3-yl)-benzoesyre; 3-((5-propenyl-[1,2,4]oxadiazol-3-yl)-benzoesyre; 3-[5-(4-chlor-benzyl)-[1,2,4]oxadiazol-3-yl]-benzoesyre; 3-[5-(4-chlor-phenoxymethyl)-[1,2,4]oxadiazol-3-yl]-benzoesyre; 3-((5-benzyl-[1,2,4]oxadiazol-3-yl)-benzoesyre; 3-((5-methoxymethyl-[1,2,4]oxadiazol-3-yl)-benzoesyre; 3-[5-(1 -phenyl-propyl)-[1,2,4]oxadiazol-3-yl]-benzoesyre; 3-[5-(4-fluor-benzyl)-[1,2,4]oxadiazol-3-yl]-benzoesyre; 3-[5-(3-chlor-phenoxymethyl)-[1,2,4]oxadiazol-3-yl]-benzoesyre; 3-((5-cyclopentylmethyl-[1,2,4]oxadiazol-3-yl)-benzoesyre; 3-[5-(4-methoxy-benzyl)-[1,2,4]oxadiazol-3-yl]-benzoesyre; 3-[5-(2,3-difluor-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoesyre; 3-[5-(2-fluor-5-methyl-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoesyre; 3- [5-(2,2-difluor-benzo[1,3]dioxol-5-yl)-[1,2,4]oxadiazol-3-yl]-benzoesyre; 4- fluor-3-[5-(4-fluor-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoesyre; 2- fluor-5-[5-(4-fluor-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoesyre; 3- [5-(4-chlor-2-fluor-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoesyre; 3-[5-(4-bromo-2-fluor-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoesyre; 3-[5-(3-fluor-biphenyl-4-yl)-[1,2,4]oxadiazol-3-yl]-benzoesyre; 3- {5-[3-(2-chlor-phenyl)-5-methyl-isoxazol-4-yl)-[1,2,4]oxadiazol-3-yl}- benzoesyre; 3-[5-(2-fluor-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoesyrenatriumsalt; 3-[5-(4-fluor-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoesyremethylester; 5- [5-(4-fluor-phenyl)-[1,2,4]oxadiazol-3-yl]-2-methoxy-benzoesyre; 3-[5-(2-fluor-6-hydroxy-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoesyre; 3-[5-(2-fluor-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoesyremethylester; 3-[5-(2-fluor-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoesyre- 2-methoxy-ethylester; 3-[5-(2-fluor-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoesyre 2-(2-methoxy-ethoxy)-ethylester; 3-[5-(2-fluor-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoesyre 2-[2-(2 methoxy- ethoxy)-ethoxy]-ethylester; 3-[5-(2-fluor-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoesyre 2-{2-[2-(2-methoxy- ethoxy)-ethoxy]-ethoxy}-ethylester; 3-[5-(2-fluor-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoesyre 2-(2-{2-[2-(2-methoxy-ethoxy)-ethoxy]-ethoxy}-ethoxy)-ethylester; 3-[5-(2-fluor-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoesyre 2-[2-(2-{2-[2-(2- hydroxy-ethoxy)-ethoxy]-ethoxy}-ethoxy)-ethoxy]-ethylester; 3-[5-(4-amino-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoesyre; 3-[5-(4-azido-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoesyre; og 3-[5-(4-benzyloxy-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoesyre og farmaceutisk acceptable salte, hydrater og solvater deraf.
6. Forbindelse ifølae krav 2 med formlen:
hvor: Z er (2-fluor-phenyl), o-tolyl, (2-chlor-phenyl), (2-methoxyphenyl) eller (2-trifluormethyl-phenyl); eller et farmaceutisk acceptabelt salt, solvat eller hydrat deraf.
7. Forbindelse ifølge krav 6 udvalgt fra 3-[5-(2-fluor-phenyl)-[1,2,4]oxadiazol- ^-x/n-honTneicx/rci morH ctri ilfti ιτοη;
eller et farmaceutisk acceptabelt salt, solvat eller hydrat deraf.
8. Farmaceutisk sammensætning omfattende forbindelsen ifølge et af kravene 1 til 7 og en farmaceutisk acceptabel bærer, excipiens eller fortyndingsmiddel.
9. Farmaceutisk sammensætning ifølge krav 8 omfattende 0,1 mg til 2000 mg af 3-[5-(2-fluor-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoesyre eller et farmaceutisk acceptabelt salt, solvat eller hydrat deraf. 7
10. Farmaceutisk sammensætning ifølge krav 9 omfattende 5 mg til 500 mg af 3-[5-(2-fluor-phenyl-[1,2,4]oxadiazol-3-yl]-benzoesyre eller et farmaceutisk acceptabelt salt, solvat eller hydrat deraf.
11. Farmaceutisk sammensætning ifølge et af kravene 8 til 10, som er fremstillet til oral, parenteral, mukosal, transdermal eller topisk indgivelse.
12. Farmaceutisk sammensætning ifølge krav 11, hvor sammensætningen er et pulver, en tablet, en kapsel eller en suspension, hvor suspensionen eventuelt er vandig.
13. Farmaceutisk sammensætning ifølge et af kravene 8 til 10, hvor sammensætningen er en steril fast eller en steril parenteral doseringsform.
14. Enkeltenhedsdoseringsform omfattende: forbindelsen ifølge et af kravene 1 til 7 og en farmaceutisk acceptabel bærer, excipiens eller fortyndingsmiddel; eller den farmaceutiske sammensætning ifølge et af kravene 8 til 13.
15. Forbindelse med formel (I):
eller et farmaceutisk acceptabelt salt, solvat eller hydrat deraf, hvor: Z er substitueret eller usubstitueret aryl, substitueret eller usubstitueret hete-roaryl udvalgt fra triazolyl, tetrazolyl, oxadiazolyl, furyl, benzofuranyl, thiophenyl, benzothiophenyl, benzoisoxazolyl, benzoisothiazolyl, quinolinyl, pyrrolyl, indolyl, oxazolyl, benzoxazolyl, imidazolyl, benzimidazolyl, thiazolyl, benzothiazolyl, isoxazolyl, pyrazolyl, isothiazolyl, pyridazinyl, pyrazinyl, triazi- nyl, cinnolinyl, phthalazinyl, quinazolinyl, benzoquinazolinyl eller acridinyl, substitueret eller usubstitueret cycloalkyl, substitueret eller usubstitueret alkenyl, substitueret eller usubstitueret heterocyklus udvalgt fra morpholinyl, pyrrolidinonyl, pyrrolidinyl, hydantoinyl, valerolactamyl, oxiranyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothiophenyl eller tetrahy-drothiopyranyl, substitueret eller usubstitueret arylalkyl; eller Z er p-tolyl; (4-chlormethyl-phenyl); (4-ethyl-phenyl); o-tolyl; (3-methyl-thiophen-2-yl); (4-tert-butyl-phenyl); m-tolyl; (2,5-dimethyl-furan-3-yl); (4-pyrrol-1 -yl-phenyl); (4-nitrophenyl); (4-isobutyl-phenyl); [3-(2-chlor-6-fluor-phenyl)-5-methyl-isoxazol-4-yl]; eller [3-(2-chlor-phenyl)-5-methyl-isoxazol-4-yl]; R1 er hydrogen, substitueret eller usubstitueret alkyl, substitueret eller usubstitueret cycloalkyl, substitueret eller usubstitueret heterocycloalkyl, substitueret eller usubstitueret aryl, substitueret eller usubstitueret heteroaryl eller -(CH2CH20)nR6; R2, R3, R4 og R5 uafhængigt er hydrogen, alkoxy eller halogen; R6 er hydrogen eller alkyl; ner et helt tal fra 1 til 7; og termen "substitueret" betyder en gruppe, som er substitueret med en til fire substituenter, udvalgt fra halogen, trifluormethyl, trifluormethoxy, hydroxy, alkoxy, cycloalkyloxy, heterocyclooxy, oxo, alkanoyl, alkylcarbonyl, cycloalkyl, aryl, aryloxy, aralkyl, alkanoyloxy, cyano, azido, amino, alkylamino, arylamino, aralkylamino, cycloalkylamino, heterocycloamino eller mono og disubstitueret amino, hvori den ene eller to substituenter på aminogruppen er udvalgt fra alkyl; hvor sådanne yderligere substituenter, når selve substituen-terne er yderligere substitueret, er udvalgt fra gruppen bestående af halogen, al kyl, alkoxy, aryl og aralkyl; til anvendelse i en fremgangsmåde til behandling eller forebyggelse af en sygdom associeret med en manglende ekspression af et gen, som er et resultat af en præmatur stopkodon, hvor sygdommen associeret med en manglende ekspression af et gen, som er et resultat af en præmatur stopkodon, er en lysosomal lagringssygdom, en kardiovaskulær sygdom, en lungesygdom, en hjertesygdom, en autoimmun sygdom, en blodsygdom, en kollagensyg-dom, diabetes, en inflammatorisk sygdom, en sygdom i centralnervesystemet, en nyresygdom, en muskeldystrofi, retinitis pigmentosa, amyloidose, kæmpevækst, dværgvækst, hypothyroidisme, hyperthyroidisme, ældning eller obesitet.
16. Forbindelse til anvendelse ifølge krav 15, hvor forbindelsen er med formel II-
(II) eller et farmaceutisk acceptabelt salt, solvat eller hydrat deraf, hvor: Z er substitueret eller usubstitueret aryl, substitueret eller usubstitueret hete-roaryl udvalgt fra triazolyl, tetrazolyl, oxadiazolyl, furyl, benzofuranyl, thiophenyl, benzothiophenyl, benzoisoxazolyl, benzoisothiazolyl, quinolinyl, pyrrolyl, indolyl, oxazolyl, benzoxazolyl, imidazolyl, benzimidazolyl, thiazolyl, benzothiazolyl, isoxazolyl, pyrazolyl, isothiazolyl, pyridazinyl, pyrazinyl, triazi-nyl, cinnolinyl, phthalazinyl, quinazolinyl, benzoquinazolinyl eller acridinyl, substitueret eller usubstitueret cycloalkyl, substitueret eller usubstitueret alkenyl, substitueret eller usubstitueret heterocyklus udvalgt fra morpholinyl, pyrrolidinonyl, pyrrolidinyl, hydantoinyl, valerolactamyl, oxiranyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothiophenyl eller tetrahy-drothiopyranyl, substitueret eller usubstitueret arylalkyl; eller Z er p-tolyl; (4-chlormethyl-phenyl); (4-ethyl-phenyl); o-tolyl; (3-methyl-thiophen-2-yl); (4-tert-butyl-phenyl); m-tolyl; (2,5-dimethyl-furan-3-yl); (4-pyrrol-1-yl-phenyl); (4-nitrophenyl); (4-isobutyl-phenyl); [3-(2-chlor-6-fluor-phenyl)-5-methyl-isoxazol-4-yl]; eller [3-(2-chlor-phenyl)-5-methyl-isoxazol-4-yl]; og R er hydrogen eller halogen;
17. Forbindelse udvalgt fra gruppen bestående af: 3-((5-p-tolyl-[1,2,4]oxadiazol-3-yl)-benzoesyre; 3-[5-(4-chlormethyl-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoesyre; 3-[5-(2-fluor-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoesyre; 3-[5-(3,4-difluor-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoesyre; 3-[5-(4-methoxy-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoesyre; 3-((5-benzo[1,3]dioxol-5-yl-[1,2,4]oxadiazol-3-yl)-benzoesyre; 3-[5-(4-ethyl-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoesyre; 3-((5-o-tolyl-[1,2,4]oxadiazol-3-yl)-benzoesyre; 3-[5-(2-chlor-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoesyre; 3-[5-(3-methyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-benzoesyre; 3-((5-benzo[b]thiophen-2-yl-[1,2,4]oxadiazol-3-yl)-benzoesyre; 3-[5-(3-fluor-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoesyre; 3-[5-(4-tert-butyl-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoesyre; 3-[5-(2-methoxy-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoesyre; 3-[5-(2,5-difluor-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoesyre; 3-((5-thiophen-2-yl-[1,2,4]oxadiazol-3-yl)-benzoesyre; 3-((5-thiophen-2-ylmethyl-[1,2,4]oxadiazol-3-yl)-benzoesyre; 3-[5-(2,4-difluor-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoesyre; 3-[5-(3-chlor-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoesyre; 3-((5-m-tolyl-[1,2,4]oxadiazol-3-yl)-benzoesyre; 3-[5-(4-trifluormethyl-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoesyre; 3-[5-(4-fluor-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoesyre; 3-[5-(3-methoxy-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoesyre; 3-[5-(2,6-difluor-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoesyre; 3-[5-(2,5-dimethyl-furan-3-yl)-[1,2,4]oxadiazol-3-yl]-benzoesyre; 3-[5-(4-pyrrol-1-yl-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoesyre; 3-[5-(3-dimethylamino-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoesyre; 3-((5-biphenyl-4-yl-[1,2,4]oxadiazol-3-yl)-benzoesyre; 3-[5-(4-dimethylamino-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoesyre; 3-((5-benzo[c][1,2,5]oxadiazol-5-yl-[1,2,4]oxadiazol-3-yl)-benzoesyre; 3-[5-(2-trifluormethyl-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoesyre; 3-((5-furan-2-yl-[1,2,4]oxadiazol-3-yl)-benzoesyre; 3-[5-(4-nitrogen-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoesyre; 3-[5-(3,4-dimethoxy-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoesyre; 3-[5-(3-trifluormethoxy-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoesyre; 3-((5-cyclohexyl-[1,2,4]oxadiazol-3-yl)-benzoesyre; 3-((5-cyclopentyl-[1,2,4]oxadiazol-3-yl)-benzoesyre; 3-((5-cyclopropyl-[1,2,4]oxadiazol-3-yl)-benzoesyre; 3-[5-(4-pentyloxy-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoesyre; 3-[5-(3,4,5-trimethoxy-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoesyre; 3-[5-(4-isobutyl-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoesyre; 3-((5-cyclobutyl-[1,2,4]oxadiazol-3-yl)-benzoesyre; 3-[5-(1-acetyl-piperidin-4-yl)-[1,2,4]oxadiazol-3-yl]-benzoesyre; 3-((5-isoxazol-5-yl-[1,2,4]oxadiazol-3-yl)-benzoesyre; 3-{5-[3-(2-chlor-6-fluor-phenyl)-5-methyl-isoxazol-4-yl]-[1,2,4]oxadiazol-3-yl}-benzoesyre; 3-((5-isopropyl-[1,2,4]oxadiazol-3-yl)-benzoesyre; 3-((5-tert-butyl-[1,2,4]oxadiazol-3-yl)-benzoesyre; 3-((5-butyl-[1,2,4]oxadiazol-3-yl)-benzoesyre; 3-((5-propenyl-[1,2,4]oxadiazol-3-yl)-benzoesyre; 3-[5-(4-chlor-benzyl)-[1,2,4]oxadiazol-3-yl]-benzoesyre; 3-[5-(4-chlor-phenoxymethyl)-[1,2,4]oxadiazol-3-yl]-benzoesyre; 3-((5-benzyl-[1,2,4]oxadiazol-3-yl)-benzoesyre; 3-((5-methoxymethyl-[1,2,4]oxadiazol-3-yl)-benzoesyre; 3-[5-(1 -phenyl-propyl)-[1,2,4]oxadiazol-3-yl]-benzoesyre; 3-[5-(4-fluor-benzyl)-[1,2,4]oxadiazol-3-yl]-benzoesyre; 3-[5-(3-chlor-phenoxymethyl)-[1,2,4]oxadiazol-3-yl]-benzoesyre; 3-((5-cyclopentylmethyl-[1,2,4]oxadiazol-3-yl)-benzoesyre; 3-[5-(4-methoxy-benzyl)-[1,2,4]oxadiazol-3-yl]-benzoesyre; 3-[5-(2,3-difluor-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoesyre; 3-[5-(2-fluor-5-methyl-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoesyre; 3- [5-(2,2-difluor-benzo[1,3]dioxol-5-yl)-[1,2,4]oxadiazol-3-yl]-benzoesyre; 4- fluor-3-[5-(4-fluor-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoesyre; 2- fluor-5-[5-(4-fluor-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoesyre; 3- [5-(4-chlor-2-fluor-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoesyre; 3-[5-(4-bromo-2-fluor-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoesyre; 3-[5-(3-fluor-biphenyl-4-yl)-[1,2,4]oxadiazol-3-yl]-benzoesyre; 3- {5-[3-(2-chlor-phenyl)-5-methyl-isoxazol-4-yl)-[1,2,4]oxadiazol-3-yl}- benzoesyre; 3-[5-(2-fluor-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoesyrenatriumsalt; 3-[5-(4-fluor phenyl)-[1,2,4]oxadiazol-3-yl]-benzoesyremethylester; 5- [5-(4-fluor-phenyl)-[1,2,4]oxadiazol-3-yl]-2-methoxy-benzoesyre; 3-[5-(2-fluor-6-hydroxy-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoesyre; 3-[5-(2-fluor-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoesyremethylester; 3-[5-(2-fluor-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoesyre- 2-methoxy-ethylester; 3-[5-(2-fluor-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoesyre 2-(2-methoxy-ethoxy)-ethylester; 3-[5-(2-fluor-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoesyre 2-[2-(2 methoxy- ethoxy)-ethoxy]-ethylester; 3-[5-(2-fluor-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoesyre 2-{2-[2-(2-methoxy- ethoxy)-ethoxy]-ethoxy}-ethylester; 3-[5-(2-fluor-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoesyre 2-(2-{2-[2-(2-methoxy-ethoxy)-ethoxy]-ethoxy}-ethoxy)-ethylester; 3-[5-(2-fluor-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoesyre 2-[2-(2-{2-[2-(2- hydroxy-ethoxy)-ethoxy]-ethoxy}-ethoxy)-ethoxy]-ethylester; 3-[5-(4-amino-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoesyre; 3-[5-(4-azido-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoesyre; og 3-[5-(4-benzyloxy-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoesyre og farmaceutisk acceptable salte, hydrater og solvater deraf til anvendelse i en fremgangsmåde til behandling eller forebyggelse af en sygdom associeret med en manglende ekspression af et gen, som er et resultat af en præmatur stopkodon, hvor sygdommen associeret med en manglende ekspression af et gen, der er et resultat af en præmatur stopkodon, er en lysosomal lagringssygdom, en kardiovaskulær sygdom, en lungesygdom, en hjertesygdom, en autoimmun sygdom, en blodsygdom, en kollagensyg-dom, diabetes, en inflammatorisk sygdom, en sygdom i centralnervesystemet, en nyresygdom, en muskeldystrofi, retinitis pigmentosa, amyloidose, kæmpevækst, dværgvækst, hypothyroidisme, hyperthyroidisme, ældning eller obesitet.
18. Forbindelse til anvendelse ifølge et af kravene 15 til 17, hvor den lysosomale lagringssygdom er tuberøs sklerose, mukopolysakkaridose type INA, mukopolysakkaridose type VI, mukopolysakkaridose type VII, metakromatisk leukodystrofi Niemann Picks sygdom eller Sandhoff-sygdom; eller hvor den autoimmune sygdom er en immundeficiens, reumatoid artritis eller graft-versus-host-sygdom; eller hvor den inflammatoriske sygdom er artritis; eller hvor sygdommen i centralnervesystemet er multipel sklerose, sen infantil neuronal ceroid lipofuscinose, Alzheimers sygdom, Tay Sachs sygdom, en neurodegenerativ sygdom eller Parkinsons sygdom; eller hvor blodsygdommen er hæmofili, Von Willebrand-sygdom, ataxia-telangiectasia eller b-thalassemia; eller hvor nyresygdommen er nyresten; eller hvor kollagensygdommen er osteogenese imperfecta, Marfan-syndrom eller cirrose; eller hvor lungesygdommen er cystisk fibrose; eller hvor muskeldystrofien er Duchenne muskeldystrofi; eller hvor den kardiovaskulære sygdom er familiær hyperkolesterolæmi eller ate- rosklerose.
19. Forbindelse med formel (I):
eller et farmaceutisk acceptabelt salt, solvat eller hydrat deraf, hvor: Z er substitueret eller usubstitueret aryl, substitueret eller usubstitueret hete-roaryl udvalgt fra triazolyl, tetrazolyl, oxadiazolyl, furyl, benzofuranyl, thiophenyl, benzothiophenyl, benzoisoxazolyl, benzoisothiazolyl, quinolinyl, pyrrolyl, indolyl, oxazolyl, benzoxazolyl, imidazolyl, benzimidazolyl, thiazolyl, benzothiazolyl, isoxazolyl, pyrazolyl, isothiazolyl, pyridazinyl, pyrazinyl, triazi-nyl, cinnolinyl, phthalazinyl, quinazolinyl, benzoquinazolinyl eller acridinyl, substitueret eller usubstitueret cycloalkyl, substitueret eller usubstitueret alkenyl, substitueret eller usubstitueret heterocyklus udvalgt fra morpholinyl, pyrrolidinonyl, pyrrolidinyl, hydantoinyl, valerolactamyl, oxiranyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothiophenyl eller tetrahy-drothiopyranyl, substitueret eller usubstitueret arylalkyl; eller Z er p-tolyl; (4-chlormethyl-phenyl); (4-ethyl-phenyl); o-tolyl; (3-methyl-thiophen-2-yl); (4-tert-butyl-phenyl); m-tolyl; (2,5-dimethyl-furan-3-yl); (4-pyrrol-1 -yl-phenyl); (4-nitrophenyl); (4-isobutyl-phenyl); [3-(2-chlor-6-fluor-phenyl)-5-methyl-isoxazol-4-yl]; eller [3-(2-chlor-phenyl)-5-methyl-isoxazol-4-yl]; R1 er hydrogen, substitueret eller usubstitueret alkyl, substitueret eller usubstitueret cycloalkyl, substitueret eller usubstitueret heterocycloalkyl, substitu- 14 eret eller usubstitueret aryl, substitueret eller usubstitueret heteroaryl eller -(CH2CH20)nR6; R2, R3, R4 og R5 uafhængigt er hydrogen, alkoxy eller halogen; R6 er hydrogen eller alkyl; n er et helt tal fra 1 til 7; og termen "substitueret" betyder en gruppe, som er substitueret med en til fire substituenter, udvalgt fra halogen, trifluormethyl, trifluormethoxy, hydroxy, alkoxy, cycloalkyloxy, heterocyclooxy, oxo, alkanoyl, alkylcarbonyl, cycloal-kyl, aryl, aryloxy, aralkyl, alkanoyloxy, cyano, azido, amino, alkylamino, arylamino, aralkylamino, cycloalkylamino, heterocycloamino eller mono og disubstitueret amino, hvori den ene eller to substituenter på aminogruppen er udvalgt fra alkyl; hvor sådanne yderligere substituenter, når selve substituen-terne er yderligere substitueret, er udvalgt fra gruppen bestående af halogen, al kyl, alkoxy, aryl og aralkyl; til anvendelse i en fremgangsmåde til behandling, forebyggelse eller lindring af kræft eller en eller flere symptomer associeret med eller former for kræft.
20. Forbindelse til anvendelse ifølge krav 19, hvor forbindelsen er med formel II-
(II) eller et farmaceutisk acceptabelt salt, solvat eller hydrater deraf, hvor: Z er substitueret eller usubstitueret aryl, substitueret eller usubstitueret heteroaryl udvalgt fra triazolyl, tetrazolyl, oxadiazolyl, furyl, benzofuranyl, thiophenyl, benzothiophenyl, benzoisoxazolyl, benzoisothiazolyl, quinolinyl, pyrrolyl, indolyl, oxazolyl, benzoxazolyl, imidazolyl, benzimidazolyl, thiazolyl, benzothiazolyl, isoxazolyl, pyrazolyl, isothiazolyl, pyridazinyl, pyrazinyl, triazi-nyl, cinnolinyl, phthalazinyl, quinazolinyl, benzoquinazolinyl eller acridinyl, substitueret eller usubstitueret cycloalkyl, substitueret eller usubstitueret al- 15 kenyl, substitueret eller usubstitueret heterocyklus udvalgt fra morpholinyl, pyrrolidinonyl, pyrrolidinyl, hydantoinyl, valerolactamyl, oxiranyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothiophenyl eller tetrahy-drothiopyranyl, substitueret eller usubstitueret arylalkyl; eller Z er p-tolyl; (4-chlormethyl-phenyl); (4-ethyl-phenyl); o-tolyl; (3-methyl-thiophen-2-yl); (4-tert-butyl-phenyl); m-tolyl; (2,5-dimethyl-furan-3-yl); (4-pyrrol-1 -yl-phenyl); (4-nitrophenyl); (4-isobutyl-phenyl); [3-(2-chlor-6-fluor-phenyl)-5-methyl-isoxazol-4-yl]; eller [3-(2-chlor-phenyl)-5-methyl-isoxazol-4-yl]; og R er hydrogen eller halogen;
21. Forbindelse til anvendelse ifølge krav 20, hvor forbindelsen er 3-[5-(2-fluor-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoesyre med strukturen:
eller et farmaceutisk acceptabelt salt, solvat eller hydrat deraf.
22. Forbindelse til anvendelse ifølge et af kravene 19 til 21, hvor kræften er hoved-halskræft, kræft i øjet, hudkræft, kræft i munden, halskræft, spiserørs-kræft, kræft i brystkassen, knoglekræft, lungekræft, tarmkræft, sigmoid-kræft, kræft i endetarmen, mavekræft, prostatakræft, brystkræft, æggestokkræft, nyrekræft, leverkræft, bugspytkirtelkræft, kræft i hjernen, tarmkræft, kræft i hjertet eller binyrer, hvor kræften er en fast tumor udvalgt fra sarkom, karci-nom, fibrosarkom, myxosarkom, liposarkom, kondrosarkom, osteogent sarkom, chordom, angiosarkom, endotheliosarkom, lymphangiosarkom, lymp-hangioendotheliosarkom, synovialom, mesothelioma, Ewings tumor, leiomy-osarkom, rhabdomyosarkom, pladecellekarcinom, basal cellekarcinom, adenokarcinom, svedkirtelkarcinom, talgkirtelkarcinom, papillært karcinom, papilllære adenokarcinomer, cystadenokarcinom, medullært karcinom, bron-chogen karcinom, nyrecellekarcinom, hepatom, galdevejskarcinom, chori-okarcinom, seminom, embryonalt karcinom, Wilms tumor, livmoderhalskræft, testikulær tumor, lungekarcinom, småcellet lungekarcinom, blærekarcinom, epithelt karcinom, gliom, astrocytom, medulloblastom, kraniofaryngeom, ependymom, Kaposis sarkom, pinealom, hemangioblastom, akustisk neu-rom, oligodendrogliom, menangiom, melanom, neuroblastom, retinoblastom, en blodbåren tumor, akut lymfoblastisk leukæmi, akut lymfoblastisk B-celle-leukæmi, akut lymfoblastisk T-celle-leukæmi, akut myeloblastisk leukæmi, akut promyelocytisk leukæmi, akut monoblastisk leukæmi, akut erythro-leukæmisk leukæmi, akut megakaryoblastisk leukæmi, akut myelomonocy-tisk leukæmi, akut ikke-lymfocyctisk leukæmi, akut udifferentieret leukæmi, kronisk myelocytisk leukæmi, kronisk lymfocytisk leukæmi, hårcelleleukæmi eller myelomatose.
23. Forbindelse til anvendelse ifølge et af kravene 15 til 22, hvor patienten er et pattedyr.
24. Forbindelse til anvendelse ifølge et af kravene 15 til 22, hvor forbindelsen er til parenteral, transdermal, mukosal, nasal, bukkal, sublingual eller oral indgivelse.
25. Forbindelse til anvendelse ifølge krav 24, hvor forbindelsen er til oral indgivelse.
26. Forbindelse til anvendelse ifølge krav 25, hvor forbindelsen er til oral indgivelse i en tablet-, flydende eller kapselform.
27. Forbindelse ifølge et af kravene 15 til 22, hvor forbindelsen er til indgivelse i en terapeutisk eller profylaktisk virksom mængde fra 1 mg til 2000 mg om dagen.
28. Forbindelse til anvendelse ifølge krav 27, hvor forbindelsen er til indgivelse i en terapeutisk eller profylaktisk virksom mængde fra 5 mg til 500 mg om dagen.
29. Forbindelse til anvendelse ifølge krav 28, hvor forbindelsen er til indgivelse i en terapeutisk eller profylaktisk virksom mængde fra 10 mg til 200 mg om dagen.
30. Forbindelse ifølge et af kravene 1 til 6, hvor R1 er H, og forbindelsen er en fri syre.
DK04759404.9T 2003-04-11 2004-04-09 1,2,4-oxadiazolbenzoesyreforbindelser og deres anvendelse til nonsens-bekæmpelse og behandling af en sygdom DK1618098T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46198803P 2003-04-11 2003-04-11
PCT/US2004/011106 WO2004091502A2 (en) 2003-04-11 2004-04-09 1,2,4-oxadiazole benzoic acid compounds

Publications (1)

Publication Number Publication Date
DK1618098T3 true DK1618098T3 (da) 2015-01-12

Family

ID=33299886

Family Applications (7)

Application Number Title Priority Date Filing Date
DK14188816.4T DK2910551T3 (da) 2003-04-11 2004-04-09 1,2,4-oxadiazol-benzoesyreforbindelser og deres anvendelse til nonsense-undertrykkelse og behandlingen af sygdom
DK17204895.1T DK3345895T3 (da) 2003-04-11 2004-04-09 1,2,4-oxadiazol-benzoesyreforbindelse og dens anvendelse til nonsense-undertrykkelse og behandlingen af sygdom
DK04759404.9T DK1618098T3 (da) 2003-04-11 2004-04-09 1,2,4-oxadiazolbenzoesyreforbindelser og deres anvendelse til nonsens-bekæmpelse og behandling af en sygdom
DK21169137.3T DK3889142T3 (da) 2003-04-11 2004-04-09 1,2,4-oxadiazolbenzoesyreforbindelser og deres anvendelse til nonsense-suppression og behandling af sygdom
DK19209758.2T DK3632902T3 (da) 2003-04-11 2004-04-09 1,2,4-oxadiazol-benzoesyreforbindelse og dens anvendelse til nonsense-undertrykkelse og behandlingen af sygdom
DK19174887.0T DK3549936T3 (da) 2003-04-11 2004-04-09 1,2,4-oxadiazol-benzoesyreforbindelse og dens anvendelse til nonsense-undertrykkelse og behandlingen af sygdom
DK16170630.4T DK3103800T3 (da) 2003-04-11 2004-04-09 1,2,4-oxadiazol-benzoesyreforbindelse og dens anvendelse til nonsense undertrykkelse og behandlingen af sygdom

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DK14188816.4T DK2910551T3 (da) 2003-04-11 2004-04-09 1,2,4-oxadiazol-benzoesyreforbindelser og deres anvendelse til nonsense-undertrykkelse og behandlingen af sygdom
DK17204895.1T DK3345895T3 (da) 2003-04-11 2004-04-09 1,2,4-oxadiazol-benzoesyreforbindelse og dens anvendelse til nonsense-undertrykkelse og behandlingen af sygdom

Family Applications After (4)

Application Number Title Priority Date Filing Date
DK21169137.3T DK3889142T3 (da) 2003-04-11 2004-04-09 1,2,4-oxadiazolbenzoesyreforbindelser og deres anvendelse til nonsense-suppression og behandling af sygdom
DK19209758.2T DK3632902T3 (da) 2003-04-11 2004-04-09 1,2,4-oxadiazol-benzoesyreforbindelse og dens anvendelse til nonsense-undertrykkelse og behandlingen af sygdom
DK19174887.0T DK3549936T3 (da) 2003-04-11 2004-04-09 1,2,4-oxadiazol-benzoesyreforbindelse og dens anvendelse til nonsense-undertrykkelse og behandlingen af sygdom
DK16170630.4T DK3103800T3 (da) 2003-04-11 2004-04-09 1,2,4-oxadiazol-benzoesyreforbindelse og dens anvendelse til nonsense undertrykkelse og behandlingen af sygdom

Country Status (30)

Country Link
US (17) US6992096B2 (da)
EP (9) EP3632902B1 (da)
JP (2) JP4851933B2 (da)
KR (1) KR101134188B1 (da)
CN (2) CN1802360B (da)
AU (1) AU2004229487B9 (da)
BE (1) BE2015C025I2 (da)
BR (1) BRPI0409319B8 (da)
CA (1) CA2521992C (da)
CR (1) CR8086A (da)
CY (6) CY1115870T1 (da)
DK (7) DK2910551T3 (da)
EA (1) EA009120B1 (da)
ES (7) ES2926542T3 (da)
FR (1) FR15C0030I2 (da)
HK (4) HK1093979A1 (da)
HU (7) HUE055056T2 (da)
IL (2) IL171343A (da)
LU (1) LU92698I2 (da)
MA (1) MA27802A1 (da)
MX (1) MXPA05010747A (da)
NO (2) NO332843B1 (da)
NZ (1) NZ543263A (da)
PL (7) PL3103800T3 (da)
PT (7) PT2910551T (da)
SI (7) SI3889142T1 (da)
TR (1) TR201706226T4 (da)
UA (1) UA84420C2 (da)
WO (1) WO2004091502A2 (da)
ZA (1) ZA200508298B (da)

Families Citing this family (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458538B1 (en) * 1999-12-14 2002-10-01 Ptc Therapeutics, Inc. Methods of assaying for compounds that inhibit premature translation termination and nonsense-mediated RNA decay
US7291461B2 (en) * 2002-06-21 2007-11-06 Ptc Therapeutics, Inc. Methods for identifying small molecules that modulate premature translation termination and nonsense mRNA decay
WO2004010106A2 (en) * 2002-07-24 2004-01-29 Ptc Therapeutics, Inc. METHODS FOR IDENTIFYING SMALL MOLEDULES THAT MODULATE PREMATURE TRANSLATION TERMINATION AND NONSENSE MEDIATED mRNA DECAY
SI3889142T1 (sl) 2003-04-11 2022-10-28 Ptc Therapeutics, Inc. Spojine 1,2,4-oksadiazol benzojske kisline in njihova uporaba za zatiranje nesmiselne ter zdravljenje bolezni
US8580842B2 (en) 2003-09-30 2013-11-12 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
JP2008515990A (ja) 2004-10-13 2008-05-15 ピーティーシー セラピューティクス，インコーポレーテッド ナンセンス抑制のための化合物およびその使用方法
CN103720688A (zh) * 2005-04-08 2014-04-16 Ptc医疗公司 用于无义突变抑制治疗的口服活性1,2,4-噁二唑组合物
AU2012238226B2 (en) * 2005-04-08 2015-05-14 Ptc Therapeutics, Inc. Compositions of an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy
CN100378084C (zh) * 2005-08-01 2008-04-02 安徽大学 2,5-二芳基取代基-1,3,4-噁二唑衍生物及其合成方法、用途
CN101420963B (zh) * 2006-02-09 2012-09-05 安佐制药股份有限公司 用于治疗乳腺癌、结肠直肠癌、胰腺癌、卵巢癌和肺癌的7-乙基-10-羟基喜树碱的多臂聚合轭合物
SG170819A1 (en) * 2006-03-30 2011-05-30 Ptc Therapeutics Inc Methods for the production of functional protein from dna having a nonsense mutation and the treatment of disorders associated therewith
BRPI0710839A2 (pt) * 2006-04-06 2011-08-23 Prosidion Ltd agonistas heterocìclicos de gpcr
US7645789B2 (en) 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
US10022352B2 (en) 2006-04-07 2018-07-17 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
PT2674428T (pt) 2006-04-07 2016-07-14 Vertex Pharma Modeladores de transportadores de cassetes de ligação de atp
WO2007130499A2 (en) * 2006-05-01 2007-11-15 Virobay, Inc. Antiviral agents
PL2059513T3 (pl) * 2006-09-08 2013-06-28 Ptc Therapeutics Inc Sposób wytwarzania pochodnych 1,2,4-oksadiazolowych kwasu benzoesowego
US8101641B2 (en) 2006-09-25 2012-01-24 Ptc Therapeutics, Inc. Hydroxylated 1,2,4-oxadiazole benzoic acid compounds and compositions thereof
JP5714228B2 (ja) * 2006-09-25 2015-05-07 ピーティーシー セラピューティクス，インコーポレーテッド ３−［５−（２−フルオロフェニル）−［１，２，４］オキサジアゾール−３−イル］−安息香酸の結晶形
AU2013219243B2 (en) * 2006-10-12 2016-09-08 Ptc Therapeutics, Inc. Methods for dosing an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy
AU2016262645B2 (en) * 2006-10-12 2018-05-17 Ptc Therapeutics, Inc. Methods for dosing an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy
DK2073805T3 (da) * 2006-10-12 2015-06-15 Ptc Therapeutics Inc Fremgangsmåder til dosering af en oralt aktiv 1,2,4-oxadiazol til terapi for suppression af nonsens-mutation
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
US20080167286A1 (en) * 2006-12-12 2008-07-10 Abbott Laboratories Pharmaceutical compositions and their methods of use
US8486979B2 (en) * 2006-12-12 2013-07-16 Abbvie Inc. 1,2,4 oxadiazole compounds and methods of use thereof
US7834039B2 (en) * 2006-12-15 2010-11-16 Abbott Laboratories Oxadiazole compounds
US20110207704A1 (en) * 2006-12-15 2011-08-25 Abbott Laboratories Novel Oxadiazole Compounds
UY30846A1 (es) 2006-12-30 2008-07-31 Abbott Gmbh & Amp Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
EP2142498A2 (en) * 2007-04-02 2010-01-13 Institute for Oneworld Health Cftr inhibitor compounds and uses thereof
WO2009000662A1 (en) * 2007-06-22 2008-12-31 F. Hoffmann-La Roche Ag Isoxazole-imidazole derivatives
CA2685599A1 (en) * 2007-07-23 2009-01-29 Summit Corporation Plc Compounds for treating duchenne muscular dystrophy
EP2170396B1 (en) 2007-08-03 2016-12-21 Summit Corporation Plc Drug combinations for the treatment of duchenne muscular dystrophy
GB0715087D0 (en) 2007-08-03 2007-09-12 Summit Corp Plc Drug combinations for the treatment of duchenne muscular dystrophy
BR122018001851B1 (pt) 2007-08-13 2019-08-20 Monsanto Technology Llc Método de controle de nematódeos parasitas de plantas
AU2008306885B2 (en) 2007-10-04 2013-12-05 Merck Serono S.A. Oxadiazole derivatives
KR20100083814A (ko) 2007-10-04 2010-07-22 메르크 세로노 에스. 에이. 옥사디아졸 디아릴 화합물
AU2008310734B2 (en) 2007-10-10 2014-06-05 Parion Sciences, Inc. Delivering osmolytes by nasal cannula
CA2705562C (en) 2007-11-16 2016-05-17 Vertex Pharmaceuticals Incorporated Isoquinoline modulators of atp-binding cassette transporters
WO2009073757A1 (en) 2007-12-07 2009-06-11 Vertex Pharmaceuticals Incorporated Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid
WO2010009775A1 (de) * 2007-12-07 2010-01-28 Abbott Gmbh & Co. Kg Carbamat-substituierte oxindol-derivate und ihre verwendung zur behandlung von vasopressin-abhängigen erkrankungen
EP2231643B1 (de) 2007-12-07 2012-10-31 Abbott GmbH & Co. KG Amidomethyl-substitutierte Oxindol-Derivate und ihre Verwendung zur Herstellung eines Medikaments zur Behandlung von Vasopressin-abhängigen Erkrankungen
ES2455197T3 (es) * 2007-12-07 2014-04-14 Abbvie Deutschland Gmbh & Co Kg Derivados de oxindol 5,6-disustituidos y el uso de los mismos para la preparación de un medicamento para el tratamiento de enfermedades dependientes de vasopresina
BRPI0820668A2 (pt) * 2007-12-07 2017-08-22 Abbott Gmbh & Co Kg Derivados de oxindol substituídos por 5-halogênio e seu uso para tratar doenças dependentes de vasopressina
AU2008340113B2 (en) * 2007-12-21 2014-01-09 Merck Serono S.A. Triazole oxadiazoles derivatives
RU2459812C2 (ru) * 2007-12-25 2012-08-27 Киссеи Фармасьютикал Ко., Лтд. Новое производное катехина, фармацевтическая композиция, содержащая производное катехина, применение производного катехина и применение фармацевтической композиции
AU2009212135B2 (en) 2008-02-07 2014-08-21 Massachusetts Eye & Ear Infirmary Compounds that enhance Atoh-1 expression
ES2552990T3 (es) 2008-03-31 2015-12-03 Vertex Pharmaceuticals Incorporated Derivados de piridilo como moduladores del CFTR
WO2009131954A2 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising oxadiazole derivatives
WO2009131956A1 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising triazole derivatives
US8207205B2 (en) * 2008-04-21 2012-06-26 Institute For Oneworld Health Compounds, compositions and methods comprising oxadiazole derivatives
WO2009131947A2 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising pyridazine derivatives
WO2009131958A2 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising triazine derivatives
US20100099677A1 (en) * 2008-04-21 2010-04-22 Institute For Oneworld Health Compounds, Compositions and Methods Comprising Thiazole Derivatives
WO2009131951A2 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising isoxazole derivatives
WO2010033626A1 (en) * 2008-09-19 2010-03-25 Institute For Oneworld Health Compounds, compositions and methods comprising imidazole and triazole derivatives
RU2531915C2 (ru) * 2008-06-09 2014-10-27 Людвиг-Максимилианс-Универзитет Мюнхен Новые лекарственные средства для ингибирования агрегации белков, вовлеченных в заболевания, связанные с агрегацией белков, и нейродегенеративные заболевания
JP5400878B2 (ja) * 2008-06-24 2014-01-29 アイアールエム・リミテッド・ライアビリティ・カンパニー Ｇタンパク質共役受容体を調節するための化合物および方法
PL2396321T3 (pl) * 2009-02-10 2015-10-30 Monsanto Technology Llc Kompozycje i sposoby zwalczania nicieni
JP5620129B2 (ja) * 2009-03-19 2014-11-05 富士フイルム株式会社 光学フィルム、位相差板、楕円偏光板、液晶表示装置、及び化合物
US8511216B2 (en) * 2009-03-30 2013-08-20 Kanzaki Kokyukoki Mfg. Co., Ltd. Hydraulic actuator unit
US8343976B2 (en) * 2009-04-20 2013-01-01 Institute For Oneworld Health Compounds, compositions and methods comprising pyrazole derivatives
EP2251437B1 (en) 2009-05-13 2013-12-04 Hannelore Breitenbach-Koller Method for identifying compounds that control the translational activity of ribosomal proteins in differential mRNA expression
US9040568B2 (en) 2009-05-29 2015-05-26 Abbvie Inc. Pharmaceutical compositions for the treatment of pain
AR076984A1 (es) 2009-06-08 2011-07-20 Merck Serono Sa Derivados de pirazol oxadiazol
US9849146B2 (en) * 2009-07-20 2017-12-26 Rutgers, The State University Of New Jersey Inhibition of nonsense mediated mRNA decay by drugs that prevent hypusination of eukaryotic initiation factor 5A
BR112012002427B1 (pt) * 2009-08-05 2021-08-31 International Paper Company Processo para preparar uma folha de polpa fofa e folha de polpa fofa preparada pelo dito processo
PL2498611T3 (pl) * 2009-11-13 2018-07-31 Celgene International Ii Sàrl Modulatory receptora sfingozyno-1-fosforanu i sposoby chiralnej syntezy
JP5650233B2 (ja) 2009-11-13 2015-01-07 レセプトス インコーポレイテッドＲｅｃｅｐｔｏｓ， Ｉｎｃ． 選択的スフィンゴシン−１−リン酸受容体変調因子および不斉合成方法
SI2826776T1 (sl) 2010-03-25 2021-02-26 Vertex Pharmaceuticals Incorporated Trdna disperzija amorfne oblike (R)-1(2,2-difluorobenzo(D)(1,3)dioksol-5-il)-N-(1-(2,3-dihidroksipropil) -6-fluoro-2-(1-hidroksi-2-metilpropan-2-il)-1H-indol-5-il)- ciklopropankarboksamida
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
PL2555754T3 (pl) 2010-04-07 2016-09-30 Formy stałe kwasu 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-ilo)cyklopropanokarboksyamido)-3-metylopirydyn-2-ylo)benzoesowego
WO2011127241A2 (en) 2010-04-07 2011-10-13 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyriodin-2-yl)benzoic acid and administration thereof
US9035072B2 (en) 2010-04-22 2015-05-19 Vertex Pharmaceuticals Incorporated Process of producing cycloalkylcarboxamido-indole compounds
US8563593B2 (en) 2010-06-08 2013-10-22 Vertex Pharmaceuticals Incorporated Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
EP2600865B1 (en) 2010-08-05 2018-11-14 Université de Lille Compound useful for the treatment of nonsense-mutation-mediated diseases and pharmaceutical composition comprising said compound
AU2011293658B2 (en) 2010-08-23 2015-03-05 Vertex Pharmaceuticals Incorporated Pharmaceutical composition of (R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxy propyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl) cyclopropanecarboxamide and administration thereof
JP6129159B2 (ja) 2011-05-13 2017-05-17 レセプトス エルエルシー 選択的複素環式スフィンゴシン１−リン酸受容体モジュレーター
US8945605B2 (en) 2011-06-07 2015-02-03 Parion Sciences, Inc. Aerosol delivery systems, compositions and methods
AU2012267938B2 (en) 2011-06-07 2017-05-04 Parion Sciences, Inc. Methods of treatment
US20140094465A1 (en) * 2011-06-10 2014-04-03 N30 Pharmaceuticals, Inc. Compounds as S-Nitrosoglutathione Reductase Inhibitors
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
KR101314488B1 (ko) * 2011-09-08 2013-10-07 중앙대학교 산학협력단 신경줄기세포 분화조절제용 신규 옥사디아졸 유도체 및 이의 의학적 용도
MX357328B (es) 2011-11-08 2018-07-05 Vertex Pharma Moduladores de trasportadores de casete enlazante de atp.
JP2015504920A (ja) 2012-01-25 2015-02-16 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ ３−（６−（１−（２，２−ジフルオロベンゾ［ｄ］［１，３］ジオキソール−５−イル）シクロプロパンカルボキサミド）−３−メチルピリジン−２−イル）安息香酸の製剤
US9598395B2 (en) 2012-03-23 2017-03-21 The Regents Of The University Of California Premature-termination-codons readthrough compounds
AU2013267504B2 (en) 2012-05-29 2017-11-02 Parion Sciences, Inc. Dendrimer like amino amides possessing sodium channel blocker activity for the treatment of dry eye and other mucosal diseases
EP2867230B1 (en) 2012-07-02 2020-02-12 Monsanto Technology LLC Process for the preparation of 3,5-disubstituted-1,2,4-oxadiazoles
US9012496B2 (en) 2012-07-16 2015-04-21 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of (R)-1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide and administration thereof
JP6302923B2 (ja) 2012-11-02 2018-03-28 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ｃｆｔｒが媒介する疾患の処置のための医薬組成物
EP2931282B1 (en) 2012-12-13 2018-10-31 Novartis AG Pyrimido [4,5-b]quinoline-4,5 (3h,10h)-diones as nonsense mutation suppressors
ES2674665T3 (es) 2012-12-17 2018-07-03 Parion Sciences, Inc. Compuestos de 3,5-diamino-6-cloro-N-(N-(4-fenilbutilo)carbamimidoilo)-pirazina-2-carboxamida
NZ709197A (en) 2012-12-17 2020-06-26 Parion Sciences Inc 3,5-diamino-6-chloro-n-(n-(4-phenylbutyl)carbamimidoyl) pyrazine-2- carboxamide compounds
MX2015007796A (es) 2012-12-17 2015-09-04 Parion Sciences Inc Derivados de cloro-pirazin carboxamida con actividad bloqueadora sobre los canales de sodio epiteliales.
US9873677B2 (en) * 2014-03-06 2018-01-23 Ptc Therapeutics, Inc. Pharmaceutical compositions and salts of a 1,2,4-oxadiazole benzoic acid
KR102456088B1 (ko) 2014-04-04 2022-10-19 델 마 파마슈티컬스 폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체
PL3424534T3 (pl) 2014-04-15 2021-11-22 Vertex Pharmaceuticals Incorporated Kompozycje farmaceutyczne do leczenia chorób, w których pośredniczy mukowiscydozowy przezbłonowy regulator przewodnictwa
WO2015186062A1 (en) 2014-06-03 2015-12-10 Novartis Ag PYRIMIDO[4,5-b]QUINOLINE-4,5(3H,10H)-DIONE DERIVATIVES
US9884862B2 (en) 2014-06-03 2018-02-06 Novartis Ag Pyridopyrimidinedione derivatives
AU2015270125B2 (en) 2014-06-03 2017-10-19 Novartis Ag Naphthyridinedione derivatives
CN105461650B (zh) * 2014-09-12 2018-04-13 杭州普晒医药科技有限公司 一种噁二唑化合物的溶剂化物及其制备方法
EP4159717A1 (en) 2014-10-06 2023-04-05 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
CN104292180A (zh) * 2014-10-12 2015-01-21 湖南华腾制药有限公司 一种恶二唑衍生物的制备方法
WO2016073470A1 (en) * 2014-11-04 2016-05-12 The University Of Kansas Lkb1-ampk activators for therapeutic use in polycystic kidney disease
WO2016073545A1 (en) * 2014-11-06 2016-05-12 Concert Pharmaceuticals, Inc. Phenyloxadiazole benzoic acids
US9994559B2 (en) * 2014-12-17 2018-06-12 King's College London Bicycloheteroaryl-heteroaryl-benzoic acid compounds as retinoic acid receptor beta (RARβ) agonists
CN106316885B (zh) * 2015-07-03 2019-02-12 普济生物科技（台州）有限公司 一种3-[5-(2-氟苯基)-1,2,4-噁二唑-3-基]苯甲酸的制备方法
CN108348527A (zh) 2015-10-30 2018-07-31 Ptc医疗公司 用于治疗癫痫的方法
EP3377476B1 (en) * 2015-11-16 2022-10-26 PTC Therapeutics, Inc. Hydrogen isotope-enriched analogues of 1,2,4-oxadiazole benzoic acid compounds, compositions and uses thereof
CA3048202A1 (en) 2015-12-23 2017-06-29 Moonshot Pharma Llc Methods for inducing an immune response by inhibition of nonsense mediated decay
TW201808922A (zh) * 2016-06-20 2018-03-16 台灣神隆股份有限公司 製備阿塔魯仁及其中間體的方法
GB201610867D0 (en) 2016-06-22 2016-08-03 King's College London Crystalline forms of a therapeutic compound and processes for their preparation
CN106279057B (zh) * 2016-08-15 2022-04-15 广州明药科技有限公司 Ataluren的合成方法
WO2018047139A1 (en) * 2016-09-12 2018-03-15 Aurigene Discovery Technologies Limited Compounds as modulators of tigit signalling pathway
US11207300B2 (en) 2016-09-13 2021-12-28 Marco Cipolli Method of treatment of Shwachman-diamond syndrome
US11439623B2 (en) 2017-04-04 2022-09-13 Case Western Reserve University Method of modulating ribonucleotide reductase
US11654135B2 (en) 2017-06-22 2023-05-23 Moonshot Pharma Llc Methods for treating colon cancer with compositions comprising amlexanox and immune checkpoint inhibitors
US11795196B2 (en) 2017-12-15 2023-10-24 Stealth Biotherapeutics Inc. Mitochondria-targeting peptides
WO2020078894A1 (en) 2018-10-15 2020-04-23 Academisch Medisch Centrum Oncotherapeutic combinations
KR102658031B1 (ko) 2018-12-27 2024-04-18 제이투에이치바이오텍 (주) 근이영양증의 치료 또는 예방에 유용한 화합물 및 이들의 의약 용도의 치료, 개선 또는 예방용 유도체
CN110987847B (zh) * 2019-12-11 2021-02-19 苏州今蓝纳米科技有限公司 1,3,4-噁二唑衍生物在检测酸以及数据加密和储存中的应用
CN111675672A (zh) * 2020-05-12 2020-09-18 石家庄市度智医药科技有限公司 一种制备阿塔鲁伦的方法
CN113045510B (zh) * 2021-03-31 2022-05-27 北京大学生命科学华东产业研究院 一种阿塔鲁伦的制备方法
EP4230196A1 (en) 2022-02-21 2023-08-23 Som Innovation Biotech, S.A. Compounds for use in the treatment of dystrophinopathies
US11932632B1 (en) 2023-10-13 2024-03-19 King Faisal University N'-(2-(5-phenyl-1,3,4-oxadiazol-2-ylthio)acetoxy)benzo[d][1,3]dioxole-5 carboximidamide as an antimicrobial compound
US11958814B1 (en) 2023-11-02 2024-04-16 King Faisal University 3-(4-nitrophenyl)-5-((2-isopropyl-5-methylphenoxy)methyl)-1,2,4-oxadiazole as an anti-cancer and antimicrobial compound

Family Cites Families (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL291628A (da) 1962-04-17
US3325446A (en) 1964-04-17 1967-06-13 Allied Chem Stabilized halogen-containing olefin polymer compositions and stabilizers therefor
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4022901A (en) 1975-03-05 1977-05-10 E. R. Squibb & Sons, Inc. 3-Pyridinyl-5-isothiocyanophenyl oxadiazoles
JPS51143669A (en) 1975-06-06 1976-12-10 Takeda Chem Ind Ltd A process for preparing 1,2,4- oxadiazole derivatives
US4016170A (en) * 1975-07-28 1977-04-05 Sandoz, Inc. Oxadiazolyl benzamides
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4135910A (en) 1977-05-12 1979-01-23 Monsanto Company Oxadiazol-3-yl-benzoates as plant growth regulants
US4166732A (en) * 1977-05-12 1979-09-04 Monsanto Company Oxadiazol-5-yl-benzoates
US4165910A (en) * 1977-10-25 1979-08-28 Bunker Ramo Corporation Electrical connector
ZA791659B (en) 1978-04-17 1980-04-30 Ici Ltd Process and apparatus for spraying liquid
US4268299A (en) 1978-08-17 1981-05-19 Monsanto Company Method and composition for plant growth regulation containing trifluoromethyl 1,3,4 oxadiazol benzoates
US4210762A (en) 1978-08-17 1980-07-01 Monsanto Company 2[5-(3-Trifluoromethylphenyl)-1,3,4-oxadiazol-2-yl] benzoates
EP0036711B1 (en) 1980-03-22 1985-12-04 Fbc Limited Pesticidal heterocyclic compounds, processes for preparing them, compositions containing them, and their use
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
GB8504253D0 (en) 1985-02-19 1985-03-20 Ici Plc Electrostatic spraying apparatus
DE3815221C2 (de) 1988-05-04 1995-06-29 Gradinger F Hermes Pharma Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
GB9225098D0 (en) 1992-12-01 1993-01-20 Coffee Ronald A Charged droplet spray mixer
GB9226717D0 (en) 1992-12-22 1993-02-17 Coffee Ronald A Induction-operated electro-hydrodynamic spray device with means of modifying droplet trajectories
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
DE4320801A1 (de) 1993-06-23 1995-01-05 Fahlberg List Pharma Gmbh 2-Hydroxyphenylsubstituierte 1,2,4-Triazole und 1,2,4-Oxadiazole, ihre Verwendung als pharmazeutische Wirkstoffe und sie enthaltende Arzneimittel
US5484944A (en) 1993-10-27 1996-01-16 Neurogen Corporation Certain fused pyrrolecarboxanilides and their use as GABA brain receptor ligands
GB9406255D0 (en) 1994-03-29 1994-05-18 Electrosols Ltd Dispensing device
GB9406171D0 (en) 1994-03-29 1994-05-18 Electrosols Ltd Dispensing device
TW343965B (en) 1994-03-30 1998-11-01 Hoffmann La Roche Novel mono- and bicyclic DNA gyrase inhibitors
GB9410658D0 (en) 1994-05-27 1994-07-13 Electrosols Ltd Dispensing device
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US6071700A (en) 1995-01-20 2000-06-06 University Of Massachusetts Heterologous polypeptide production in the absence of nonsense-mediated MRNA decay functions
JP3585127B2 (ja) 1995-03-14 2004-11-04 シーメンス アクチエンゲゼルシヤフト 超音波噴霧システム
WO1996028205A1 (en) 1995-03-14 1996-09-19 Siemens Aktiengesellschaft Ultrasonic atomizer device with removable precision dosing unit
WO1997009335A1 (en) 1995-09-07 1997-03-13 Novartis Ag Substituted phosphinic compounds and their use as pharmaceuticals
WO1997039745A1 (en) 1996-04-19 1997-10-30 Sloan-Kettering Institute For Cancer Research Use of inhaled retinoids in the prevention of cancer
WO1997041105A1 (fr) * 1996-04-26 1997-11-06 Nippon Soda Co., Ltd. Nouveaux derives de benzene a substitution heterocycle et herbicides
DE19620041A1 (de) * 1996-05-17 1998-01-29 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
US6034106A (en) 1996-06-07 2000-03-07 Merck & Co., Inc. Oxadiazole benzenesulfonamides as selective β3 Agonist for the treatment of Diabetes and Obesity
CA2257206A1 (en) 1996-06-07 1997-12-11 Gui-Bai Liang Oxadiazole benzenesulfonamides as selective .beta.3 agonists for the treatment of diabetes and obesity
DE19626318A1 (de) 1996-07-01 1998-01-08 Basf Ag Farbstoffmischungen, enthaltend Polyazofarbstoffe
ZA98371B (en) 1997-01-31 1999-07-16 Du Pont Genetically transformed plants demonstrating resistance to porphyrinogen biosynthesis-inhibiting herbicides.
DK0975595T3 (da) 1997-04-07 2009-10-19 Univ Georgetown Kokainanaloger
US6004933A (en) 1997-04-25 1999-12-21 Cortech Inc. Cysteine protease inhibitors
NZ504021A (en) 1997-10-17 2003-04-29 Systemic Pulmonary Delivery Lt Method and apparatus for delivering aerosolized medication having air discharged through air tube directly into plume of aerosolized medication
AU9647998A (en) * 1997-10-27 1999-05-17 Nippon Soda Co., Ltd. Novel benzoylpyrazole derivatives and herbicides
BR9908771A (pt) 1998-03-16 2000-12-12 Inhale Therapeutic Syst Processos para a liberação de um agente ativo e de insulina para os pulmões de um paciente humano, dispositivo para aumentar a biodisponibilidade de um agente ativo, e, dispositivos para a liberação de um agente ativo e de insulina para os pulmões de um paciente humano
NZ507696A (en) 1998-04-23 2003-10-31 Cortech Inc Triazole, oxadiazole and thiadiazole derivatives useful as cysteine protease inhibitors
ATE316969T1 (de) 1998-10-08 2006-02-15 Smithkline Beecham Plc Tetrahydrobenzazepin-derivate verwendbar als dopamin-d3-rezeptor-modulatoren (antipsychotische mittel)
JP2002527438A (ja) 1998-10-09 2002-08-27 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ４，５−ジヒドロ−イソオキサゾール誘導体及びそれらの製薬学的使用
EP1126833A4 (en) 1998-10-29 2004-09-08 Trega Biosciences Inc OXADIAZOLE, THIADIAZOLE AND TRIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES CONTAINING THESE DERIVATIVES
CZ20012277A3 (cs) 1998-12-23 2001-11-14 Smithkline Beecham Corporation Inhibitory proteázy
AU3196200A (en) 1999-03-26 2000-10-16 Shionogi & Co., Ltd. Beta-amino acid derivatives
WO2000058304A1 (fr) 1999-03-26 2000-10-05 Shionogi & Co., Ltd. Derives sulfonamides heterocycliques
WO2000058280A1 (fr) 1999-03-26 2000-10-05 Shionogi & Co., Ltd. Derives de sulfonamide carbocyclique
ATE307798T1 (de) 1999-05-17 2005-11-15 Novo Nordisk As Glucagon antagonisten/inverse agonisten
UA71971C2 (en) 1999-06-04 2005-01-17 Agoron Pharmaceuticals Inc Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases
JP2001247569A (ja) 1999-08-12 2001-09-11 Japan Tobacco Inc ピロリジン誘導体又はピペリジン誘導体及びその医薬用途
US6660753B2 (en) 1999-08-19 2003-12-09 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
US6458538B1 (en) 1999-12-14 2002-10-01 Ptc Therapeutics, Inc. Methods of assaying for compounds that inhibit premature translation termination and nonsense-mediated RNA decay
WO2001066534A2 (en) 2000-03-09 2001-09-13 Abbott Laboratories Cyclic and bicyclic diamino histamine-3 receptor antagonists
EP1268495A1 (en) 2000-03-22 2003-01-02 Merck Frosst Canada Inc. Sulfur substituted aryldifluoromethylphosphonic acids as ptp-1b inhibitors
AU2001248765A1 (en) * 2000-04-21 2001-11-12 Shionogi And Co., Ltd. Oxadiazole derivatives having therapeutic or preventive efficacies against glomerular disorders
GB0011089D0 (en) * 2000-05-08 2000-06-28 Black James Foundation Gastrin and cholecystokinin receptor ligands (11)
OA12274A (en) 2000-05-22 2006-05-09 Aventis Pharma Inc Arylmethylamine derivatives for use as tryptase inhibitors.
CN1328143A (zh) 2000-06-12 2001-12-26 上海博德基因开发有限公司 一种新的多肽——人甲基化－dna－蛋白－半胱氨酸甲基转移酶13和编码这种多肽的多核苷酸
JP2002105073A (ja) 2000-09-27 2002-04-10 Shionogi & Co Ltd 新規マトリックスメタロプロテアーゼ阻害剤
AUPR362001A0 (en) 2001-03-08 2001-04-05 Fujisawa Pharmaceutical Co., Ltd. New compound
CA2342432A1 (en) 2001-03-28 2002-09-28 Christopher Norbert Johnson Novel compound
GB0108102D0 (en) * 2001-03-30 2001-05-23 Pfizer Ltd Compounds
JP4480941B2 (ja) 2001-04-19 2010-06-16 アイキュリス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング・ウント・コムパニー・コマンディットゲゼルシャフト 抗ウイルス剤としての新規アリールスルホンアミド
MXPA03011196A (es) 2001-06-08 2004-10-28 Cytovia Inc 3-aril-5-aril-[1,2,4]-oxadiazoles sustituidos y analogos.
JP2003081832A (ja) * 2001-06-26 2003-03-19 Takeda Chem Ind Ltd レチノイド関連受容体機能調節剤
GB0115862D0 (en) 2001-06-28 2001-08-22 Smithkline Beecham Plc Compounds
MY151199A (en) 2001-11-02 2014-04-30 Rigel Pharmaceuticals Inc Substituted diphenyl heterocycles useful for treating hcv infection
BR0313266A (pt) 2002-08-09 2005-06-21 Astrazeneca Ab Compostos, respectivos processos de preparação e uso, formulação farmacêutica e métodos de prevenção e/ou tratamento de um distúrbio mediado pelo receptor de mglur5 e de inibição da ativação de receptores de mglur5
US7074809B2 (en) 2002-08-09 2006-07-11 Astrazeneca Ab Compounds
GB0303503D0 (en) 2003-02-14 2003-03-19 Novartis Ag Organic compounds
EA200501376A1 (ru) 2003-03-28 2006-04-28 Пфайзер Продактс Инк. Производные 1,2,4-замещённых 1,2,3,4-тетрагидро- и 1,2-дигидрохинолинов и 1,2,3,4-тетрагидрохиноксалина в качестве ингибиторов сетр для лечения атеросклероза и тучности
SI3889142T1 (sl) * 2003-04-11 2022-10-28 Ptc Therapeutics, Inc. Spojine 1,2,4-oksadiazol benzojske kisline in njihova uporaba za zatiranje nesmiselne ter zdravljenje bolezni
US20050075375A1 (en) 2003-05-14 2005-04-07 Anadys Pharmaceuticals, Inc. Heterocyclic compounds for treating hepatitis C virus
WO2005060961A2 (en) 2003-12-18 2005-07-07 Astrazeneca Ab Treatment of transient lower esophageal sphincter relaxations (tlesrs) and gastro-esophageal reflux disease (gerd)
US7745630B2 (en) 2003-12-22 2010-06-29 Justin Stephen Bryans Triazolyl piperidine arginine vasopressin receptor modulators
WO2005077373A2 (en) 2004-02-03 2005-08-25 Astrazeneca Ab Treatment of gastro-esophageal reflux disease (gerd)
JP2008515990A (ja) 2004-10-13 2008-05-15 ピーティーシー セラピューティクス，インコーポレーテッド ナンセンス抑制のための化合物およびその使用方法
CN103720688A (zh) 2005-04-08 2014-04-16 Ptc医疗公司 用于无义突变抑制治疗的口服活性1,2,4-噁二唑组合物
SG170819A1 (en) 2006-03-30 2011-05-30 Ptc Therapeutics Inc Methods for the production of functional protein from dna having a nonsense mutation and the treatment of disorders associated therewith
WO2007123848A2 (en) 2006-04-19 2007-11-01 Brown University Therapeutic compositions containing modified class i slrp proteins
PL2059513T3 (pl) * 2006-09-08 2013-06-28 Ptc Therapeutics Inc Sposób wytwarzania pochodnych 1,2,4-oksadiazolowych kwasu benzoesowego
JP5714228B2 (ja) 2006-09-25 2015-05-07 ピーティーシー セラピューティクス，インコーポレーテッド ３−［５−（２−フルオロフェニル）−［１，２，４］オキサジアゾール−３−イル］−安息香酸の結晶形
DK2073805T3 (da) 2006-10-12 2015-06-15 Ptc Therapeutics Inc Fremgangsmåder til dosering af en oralt aktiv 1,2,4-oxadiazol til terapi for suppression af nonsens-mutation
WO2008127364A2 (en) 2006-10-13 2008-10-23 Myriad Genetics, Inc. Antiviral compounds and use thereof
US20110177999A1 (en) 2007-08-09 2011-07-21 Vertex Pharmaceuticals Incorporated Therapeutic Combinations Useful in Treating CFTR Related Diseases
AU2008306885B2 (en) 2007-10-04 2013-12-05 Merck Serono S.A. Oxadiazole derivatives
PT2203173E (pt) 2007-10-26 2016-03-15 Academisch Ziekenhuis Leiden Resumo
JP5560201B2 (ja) 2007-12-17 2014-07-23 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 骨格筋欠損症を治療および予防するための組成物および方法
JP5400878B2 (ja) 2008-06-24 2014-01-29 アイアールエム・リミテッド・ライアビリティ・カンパニー Ｇタンパク質共役受容体を調節するための化合物および方法
HUE038428T2 (hu) 2008-10-07 2018-10-29 Horizon Orphan Llc Aeroszol fluorokinolon készítmények javított farmakokinetika érdekében
RU2398770C1 (ru) 2009-03-27 2010-09-10 Учреждение Российской академии наук Институт молекулярной генетики РАН (ИМГ РАН) Меченная тритием 3-[5-(2-фторфенил)-1,2,4-оксадиазол-3-ил]бензойная кислота

Also Published As

Publication number Publication date
PL3632902T3 (pl) 2021-12-20
US8017636B2 (en) 2011-09-13
ES2770035T3 (es) 2020-06-30
US20130289007A1 (en) 2013-10-31
PT2910551T (pt) 2017-05-22
CY1120446T1 (el) 2019-07-10
SI3889142T1 (sl) 2022-10-28
US20120277234A1 (en) 2012-11-01
EP1618098A4 (en) 2008-07-16
KR101134188B1 (ko) 2012-04-12
DK3632902T3 (da) 2021-09-13
NO20055314L (no) 2006-01-04
US9861617B2 (en) 2018-01-09
PT3345895T (pt) 2020-01-29
DK3549936T3 (da) 2021-07-12
JP5436500B2 (ja) 2014-03-05
PT3103800T (pt) 2018-07-27
NO20055314D0 (no) 2005-11-10
CN1802360B (zh) 2014-05-07
LU92698I2 (fr) 2015-06-22
SI1618098T1 (sl) 2015-04-30
HK1214253A1 (zh) 2016-07-22
SI3549936T1 (sl) 2021-09-30
HUE047569T2 (hu) 2020-04-28
US8975287B2 (en) 2015-03-10
EP3178816A1 (en) 2017-06-14
SI3345895T1 (sl) 2020-03-31
PL3103800T3 (pl) 2018-11-30
CA2521992C (en) 2013-02-05
CY1119001T1 (el) 2018-01-10
HUE031794T2 (en) 2017-08-28
EP1618098A2 (en) 2006-01-25
HUE055434T2 (hu) 2021-11-29
PL1618098T3 (pl) 2015-04-30
US20180092887A1 (en) 2018-04-05
PL3549936T3 (pl) 2021-11-08
US8796322B2 (en) 2014-08-05
CY2015017I1 (el) 2016-06-22
EP3549936B1 (en) 2021-06-02
HUE039026T2 (hu) 2018-12-28
US9205088B2 (en) 2015-12-08
CN104056278B (zh) 2017-01-18
BRPI0409319A (pt) 2006-04-25
US7683082B2 (en) 2010-03-23
ES2926542T3 (es) 2022-10-26
US8129540B2 (en) 2012-03-06
FR15C0030I1 (da) 2015-05-22
HK1202254A1 (en) 2015-09-25
CN1802360A (zh) 2006-07-12
DK3345895T3 (da) 2020-02-03
ES2881198T3 (es) 2021-11-29
ES2679108T3 (es) 2018-08-22
EP3632902A1 (en) 2020-04-08
CY1122659T1 (el) 2020-10-14
WO2004091502A3 (en) 2004-12-29
DK3889142T3 (da) 2022-09-12
US7202262B2 (en) 2007-04-10
US8227494B2 (en) 2012-07-24
PT3549936T (pt) 2021-07-14
HK1257517A1 (zh) 2019-10-25
EP3103800B1 (en) 2018-06-13
US8486982B2 (en) 2013-07-16
FR15C0030I2 (fr) 2015-07-24
US20060148863A1 (en) 2006-07-06
US6992096B2 (en) 2006-01-31
BRPI0409319B8 (pt) 2021-05-25
NZ543263A (en) 2008-12-24
KR20060009838A (ko) 2006-02-01
TR201706226T4 (tr) 2018-06-21
AU2004229487B9 (en) 2010-06-10
JP4851933B2 (ja) 2012-01-11
US7419991B2 (en) 2008-09-02
EP3889142A1 (en) 2021-10-06
EA200501601A1 (ru) 2006-06-30
CY2015017I2 (el) 2016-06-22
AU2004229487A1 (en) 2004-10-28
BRPI0409319B1 (pt) 2019-11-12
US20120178080A1 (en) 2012-07-12
PT1618098E (pt) 2015-02-10
PT3889142T (pt) 2022-08-22
DK2910551T3 (da) 2017-05-15
CY1124464T1 (el) 2022-07-22
US20160081988A1 (en) 2016-03-24
US10071081B2 (en) 2018-09-11
US20140301978A1 (en) 2014-10-09
EP2910551A1 (en) 2015-08-26
AU2004229487B2 (en) 2010-05-20
PT3632902T (pt) 2021-09-15
MA27802A1 (fr) 2006-03-01
US7304080B2 (en) 2007-12-04
US20100168109A1 (en) 2010-07-01
US20100216851A1 (en) 2010-08-26
EP1618098B1 (en) 2014-11-19
US20040204461A1 (en) 2004-10-14
CR8086A (es) 2006-12-19
EP2910551B1 (en) 2017-02-15
HK1093979A1 (en) 2007-03-16
HUS1500021I1 (hu) 2017-04-28
EP4101846B1 (en) 2023-08-02
NO2015002I1 (no) 2015-02-16
WO2004091502A8 (en) 2005-11-24
CY1115870T1 (el) 2016-06-22
IL225161A (en) 2014-03-31
US20050164973A1 (en) 2005-07-28
US8299105B2 (en) 2012-10-30
ES2528195T3 (es) 2015-02-05
DK3103800T3 (da) 2018-07-30
NO332843B1 (no) 2013-01-21
WO2004091502A2 (en) 2004-10-28
HUE059464T2 (hu) 2022-11-28
HUE055056T2 (hu) 2021-10-28
JP2011251981A (ja) 2011-12-15
US7772259B2 (en) 2010-08-10
EP3345895B1 (en) 2019-12-04
CA2521992A1 (en) 2004-10-28
NO2015002I2 (no) 2015-02-03
ES2887054T3 (es) 2021-12-21
EA009120B1 (ru) 2007-10-26
ES2624610T3 (es) 2017-07-17
JP2006522826A (ja) 2006-10-05
US20100121070A1 (en) 2010-05-13
BE2015C025I2 (da) 2023-08-09
SI3103800T1 (sl) 2018-10-30
US20110311486A1 (en) 2011-12-22
UA84420C2 (ru) 2008-10-27
MXPA05010747A (es) 2006-05-25
US20060148864A1 (en) 2006-07-06
EP3632902B1 (en) 2021-07-14
US8163782B2 (en) 2012-04-24
CN104056278A (zh) 2014-09-24
EP4101846A1 (en) 2022-12-14
ZA200508298B (en) 2007-01-31
EP3889142B1 (en) 2022-06-15
PL3889142T3 (pl) 2022-09-26
IL171343A (en) 2013-06-27
EP3549936A1 (en) 2019-10-09
SI2910551T1 (sl) 2017-07-31
PL3345895T3 (pl) 2020-05-18
US20070161687A1 (en) 2007-07-12
EP3345895A1 (en) 2018-07-11
US20060035943A1 (en) 2006-02-16
EP3103800A1 (en) 2016-12-14
US20150148346A1 (en) 2015-05-28
PL2910551T3 (pl) 2017-09-29
SI3632902T1 (sl) 2022-01-31

Similar Documents

Publication Publication Date Title
US10071081B2 (en) Compositions of 1,2,4-oxadiazole benzoic acid compounds and methods for their use